Biotech's most exciting startups of 2026: Meet this year's Endpoints 11
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Evidence dossier
Intelligence passport
Measured timeline
Who reported it (5)
-
Endpoints News Announces the 2026 Winners of the Endpoints 11 Awards, showcasing biotech’s most exciting startupsThe National Law Review · 1d ago
-
-
K2 Therapeutics Recognized as a 2026 Endpoints 11 HonoreeThe Manila Times · 1d ago
-
Corsera Health Named a 2026 “Endpoints 11” HonoreeBusiness Wire · 1d ago
-
Biotech's most exciting startups of 2026: Meet this year's Endpoints 11Endpoints News · 1d ago
The story so far
- Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: 5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"Biotech's most exciting startups of 2026: Meet this year's Endpoints 11" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by Archynetys so far.
Outlets currently covering the story include The National Law Review, TipRanks, The Manila Times and Business Wire. Archynetys measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
Synthesized from multi-source international reporting and live coverage telemetry under Archynetys open intelligence methodology.
Generated by Archynetys's extractive engine from coverage metadata only — no AI-written claims. Updated 44m ago.
The obvious questions
Why is "Biotech's most exciting startups of 2026: Meet this year's Endpoints 11" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst Archynetys classifies as a trend.
How does Archynetys measure this trend?
Archynetys scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
Meet the USMNT’s next generation: a cheat sheet for 12 new players in camp
5 news sources are covering this Sports story right now — Archynetys is tracking how fast it spreads.
Meet the Muse mascot, Jolly. Who doesn't love a little guy?
5 news sources are covering this Technology story right now — Archynetys is tracking how fast it spreads.
FDA panel endorses first-of-a-kind cancer blood test from Grail
FDA panel endorses first-of-a-kind cancer blood test from Grail, but controversy lingers.
Nvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking details
Nvidia-backed Iambic Therapeutics' IPO filing surprises with disclosed clinic and dealmaking details amid a biotech IPO surge
Novartis secures new radioligand in $900M deal as competition strengthens
Novartis’s $900 million BoomRay radioligand deal spotlights a China-origin, preclinical asset amid mounting competition in the biotech field
Exclusive
19 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.